Details of the Drug

General Information of Drug (ID: DMQ0RKZ)

Drug Name
Nimodipine
Synonyms
Admon; Brainal; Calnit; Kenesil; Modus; NimoGel; NimodipinISIS; Nimodipino; Nimodipinum; Nimotop; Periplum; Remontal; Almirall Brand of Nimodipine; Alpharma Brand of Nimodipine; Andromaco Brand of Nimodipine; Bayer Brand of Nimodipine; Bayvit Brand of Nimodipine; Cantabria Brand of Nimodipine; Elan Brand of Nimodipine; Esteve Brand of Nimodipine; Hexal Brand of Nimodipine; Nimodipin Hexal; Nimodipin ISIS; Nimodipino Bayvit; Vita Brand of Nimodipine; Bay-E 9736; DRG-0139; EG-1961; N-149; NIMOTOP (TN); Nimodipin-ISIS; Nimodipino [INN-Spanish]; Nimodipinum [INN-Latin]; Nimotop (TN); Nimotop(TM); Nimotop, Nimodipine; Bay-e-9736; Nimodipine (USAN/INN); Nimodipine [USAN:BAN:INN]; Periplum, Nimotop, BRN 0459792, DRG-0139; Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl-1-methylethyl Ester; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester;1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 2-Methoxyethyl-1-methylethyl ester; 2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester; 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,2-methoxyethyl 1-methylethyl ester; 3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester; 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl), 2-methoxyethyl 1-methylethyl ester; 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-N,N-dimethyl-2,2-diphenyl-butanamide
Indication
Disease Entry ICD 11 Status REF
Cerebral vasospasm BA85.Z Approved [1]
Therapeutic Class
Vasodilator Agents
Affected Organisms
Humans and other mammals
ATC Code
C08CA06: Nimodipine
C08CA: Dihydropyridine derivatives
C08C: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08: CALCIUM CHANNEL BLOCKERS
C: CARDIOVASCULAR SYSTEM
C08CA06: Nimodipine
C08CA: Dihydropyridine derivatives
C08C: SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08: CALCIUM CHANNEL BLOCKERS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 418.4
Logarithm of the Partition Coefficient (xlogp) 3.1
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 15 mL/min/kg [3]
Elimination
0.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.7 - 9 hours [3]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.33861 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.016% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.1 L/kg [3]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0025 mg/mL [2]
Chemical Identifiers
Formula
C21H26N2O7
IUPAC Name
3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
InChI
InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3
InChIKey
UIAGMCDKSXEBJQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4497
ChEBI ID
CHEBI:7575
CAS Number
66085-59-4
UNII
57WA9QZ5WH
DrugBank ID
DB00393
TTD ID
D0XN1F
VARIDT ID
DR01211
INTEDE ID
DR1161
ACDINA ID
D00470
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium channel unspecific (CaC) TT5HONZ NOUNIPROTAC Blocker [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [9]
Anoctamin-1 (ANO1) OTSREUNI ANO1_HUMAN Gene/Protein Processing [10]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [11]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [11]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [9]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [12]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [12]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [10]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Gene/Protein Processing [13]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Gene/Protein Processing [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MCF-7 CTRP1 6.6873 8.6255 4.3804 1.8462
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LN-229 CTRP1 7.0859 9.7098 4.1265 2.8604
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP1 7.0451 12.1121 3.0183 10.9504
Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PL21 CTRP1 5.6009 8.4633 3.7846 9.3713
OCI-AML-3 CTRP1 5.9401 9.4672 3.5389 10.286
WSU-DLCL2 CTRP1 6.068 7.5275 4.5294 1.8785
U-937 CTRP1 6.181 10.1666 3.369 10.8739
THP-1 CTRP1 6.2369 8.1575 4.3462 2.8831
SKM-1 CTRP1 6.3773 8.1184 4.4379 1.9631
EJM CTRP1 6.4394 9.1195 4.0311 4.8522
SU-DHL-4 CTRP1 6.5747 7.9344 4.6038 0.7322
SU-DHL-5 CTRP1 6.5857 7.4442 4.7842 0.111
NOMO-1 CTRP1 6.6955 8.2604 4.5303 0.974
GDM-1 CTRP1 6.7627 9.9551 3.8427 5.5454
MOLM-16 CTRP1 6.7891 8.5242 4.4686 1.1953
RPMI-8226 CTRP1 6.9855 14.6958 1.7364 19.0604
NU-DUL-1 CTRP1 7.0125 8.5777 4.5426 0.6351
⏷ Show the Full List of 14 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CW-2 CTRP1 6.5571 8.4164 4.4032 1.9
SNU-C4 CTRP1 6.6505 7.6228 4.7461 0.171
HT115 CTRP1 6.7044 8.0727 4.6055 0.6117
SW948 CTRP1 6.7169 8.0117 4.633 0.4905
MDST8 CTRP1 6.7949 8.3606 4.5344 0.8537
RCM-1 [Human ESC] CTRP1 6.8999 8.5117 4.5212 0.819
SNU-81 CTRP1 6.9657 8.9211 4.3913 1.4101
HCT 116 CTRP1 6.9928 8.8316 4.4383 1.13
HT-55 CTRP1 7.0284 8.5519 4.5583 0.5622
SNU-1040 CTRP1 7.1119 8.4691 4.6197 0.3123
HCT 8 CTRP1 7.1125 8.097 4.746 0.0651
SNU-175 CTRP1 7.1283 8.68 4.5508 0.5245
SNU-61 CTRP1 7.1299 8.7978 4.5083 0.6862
CL-40 CTRP1 7.1345 8.8739 4.4819 0.7931
SW480 CTRP1 7.219 10.8209 3.7166 5.4686
CL-34 CTRP1 7.2589 8.7888 4.5616 0.4134
HT-29 CTRP1 7.2715 8.4983 4.6666 0.1502
NCI-H508 CTRP1 7.3012 8.7041 4.6069 0.2682
COLO 678 CTRP1 7.3244 9.4604 4.3389 1.2879
COLO 320 CTRP1 7.3497 9.8276 4.2056 1.9811
LS123 CTRP1 7.4015 8.9211 4.5679 0.3284
SW620 CTRP1 7.4824 8.9747 4.5786 0.2698
RKO CTRP1 7.6366 9.0945 4.5922 0.1928
LoVo CTRP1 7.652 9.8591 4.3253 1.0456
KM12 CTRP1 7.6846 9.286 4.5438 0.2799
SNU-C5 CTRP1 7.7442 9.4597 4.5053 0.3522
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Hep-G2 CTRP1 6.3709 7.8793 4.534 1.3528
Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC1359 CTRP1 6.1893 7.3732 4.6533 0.8908
NCI-H2110 CTRP1 6.214 8.3177 4.2617 3.5778
NCI-H460 CTRP1 6.5779 9.6043 3.8926 5.5997
NCI-H596 CTRP1 6.5972 8.319 4.4626 1.4705
NCI-H841 CTRP1 6.6802 8.8025 4.3032 2.3593
NCI-H1105 CTRP1 6.6926 19.1749 -0.6882 29.3646
Sq-1 CTRP1 6.7127 7.9582 4.6509 0.4263
HCC2108 CTRP1 6.801 8.9487 4.3024 2.1699
HCC2935 CTRP1 6.8143 8.401 4.5273 0.8695
NCI-H1836 CTRP1 6.8487 8.1875 4.6206 0.4496
NCI-H1694 CTRP1 6.8944 8.4105 4.5569 0.6664
NCI-H3255 CTRP1 6.9222 9.1255 4.2885 2.0739
T3M-10 CTRP1 6.9371 9.534 4.1248 3.1265
COR-L23 CTRP1 6.939 8.3623 4.5923 0.4945
NCI-H2172 CTRP1 6.9457 11.7909 3.1055 10.6026
NCI-H2073 CTRP1 7.0502 9.0692 4.3708 1.4223
NCI-H1781 CTRP1 7.0583 9.2065 4.3199 1.6977
NCI-H1755 CTRP1 7.0782 8.787 4.4914 0.7985
HCC4006 CTRP1 7.118 8.7427 4.5239 0.6329
NCI-H1876 CTRP1 7.1377 9.0204 4.4279 1.0366
HCC1195 CTRP1 7.1535 8.656 4.5691 0.4463
HCC1833 CTRP1 7.2325 9.8106 4.157 2.4355
HCC827 CTRP1 7.3261 9.2179 4.4317 0.8532
NCI-H2122 CTRP1 7.3946 8.7818 4.6135 0.2204
NCI-H2081 CTRP1 7.4551 9.5433 4.3627 1.0487
NCI-H2342 CTRP1 7.513 9.2796 4.4828 0.5302
COLO 699 CTRP1 7.5963 9.3474 4.4901 0.462
CAL-12T CTRP1 7.6113 9.2243 4.5388 0.3192
NCI-H2030 CTRP1 7.7071 9.2591 4.561 0.2348
HCC15 CTRP1 7.717 10.3089 4.1808 1.6788
NCI-H2023 CTRP1 7.776 9.4183 4.531 0.278
NCI-H441 CTRP1 7.8677 9.4497 4.5525 0.2059
SK-LU-1 CTRP1 8.0552 9.6791 4.5402 0.1816
⏷ Show the Full List of 33 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHOM-1 CTRP1 6.1336 8.9419 3.9234 6.5148
OAW42 CTRP1 6.3969 7.7652 4.5919 0.9815
OV-90 CTRP1 6.5335 8.7273 4.2589 2.9302
TYK-nu CTRP1 6.9908 8.7205 4.4801 0.927
OV7 CTRP1 7.095 9.5775 4.1862 2.4589
COV434 CTRP1 7.1352 10.4985 3.8125 4.9532
OVK18 CTRP1 7.1384 8.9544 4.4533 0.917
JHOC-5 CTRP1 7.3368 10.0199 4.1214 2.5027
EFO-27 CTRP1 7.4268 12.9794 2.8551 11.0597
COV362 CTRP1 7.5214 9.0577 4.564 0.2908
COV644 CTRP1 7.5389 8.9523 4.6062 0.1925
RMUG-S CTRP1 7.5812 12.0329 3.382 7.062
Caov-3 CTRP1 7.8264 9.316 4.5833 0.1621
RMG-I CTRP1 7.8875 9.7266 4.4646 0.4005
SNU-840 CTRP1 7.906 12.1811 3.4971 5.6117
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-MEL-28 CTRP1 5.9838 6.7961 4.7878 0.4159
SK-MEL-1 CTRP1 6.8625 8.5472 4.4918 0.9953
SK-MEL-5 CTRP1 7.1246 8.3275 4.6731 0.1777
A-375 CTRP1 7.1326 8.6642 4.5581 0.4958
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HT-1080 CTRP1 7.0726 8.4588 4.6088 0.3629

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Nimodipine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cefuroxime DMSIMD8 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefuroxime. Acute bronchitis [CA42] [15]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Nimodipine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [16]
Arn-509 DMT81LZ Major Increased metabolism of Nimodipine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [17]
Magnesium Sulfate DMVEK07 Moderate Additive neuromuscular blocking effects by the combination of Nimodipine and Magnesium Sulfate. Acute pain [MG31] [18]
Emapalumab DMZG5WL Moderate Altered metabolism of Nimodipine due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [19]
Mitotane DMU1GX0 Major Increased metabolism of Nimodipine caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [17]
Framycetin DMF8DNE Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Framycetin. Alcoholic liver disease [DB94] [15]
Cefamandole DMNEXZF Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefamandole. Anaerobic bacterial infection [1A00-1A09] [15]
Siltuximab DMGEATB Moderate Altered metabolism of Nimodipine due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [19]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Nimodipine caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [20]
Promazine DMZAL7W Moderate Additive hypotensive effects by the combination of Nimodipine and Promazine. Appearance/behaviour symptom [MB23] [21]
Voriconazole DMAOL2S Major Decreased metabolism of Nimodipine caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [22]
Posaconazole DMUL5EW Major Decreased metabolism of Nimodipine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [22]
Zileuton DMVRIC2 Minor Decreased metabolism of Nimodipine caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [23]
Cefotetan DM07TX3 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefotetan. Bacterial infection [1A00-1C4Z] [15]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Kanamycin. Bacterial infection [1A00-1C4Z] [15]
Ceftazidime DM41GRA Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Ceftazidime. Bacterial infection [1A00-1C4Z] [15]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Nimodipine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Clarithromycin DM4M1SG Major Decreased metabolism of Nimodipine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Cefoperazone DM53PV8 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefoperazone. Bacterial infection [1A00-1C4Z] [15]
Amikacin DM5PDRB Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Amikacin. Bacterial infection [1A00-1C4Z] [15]
Cefprozil DM7DSYP Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefprozil. Bacterial infection [1A00-1C4Z] [15]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Streptomycin. Bacterial infection [1A00-1C4Z] [15]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Nimodipine and Linezolid. Bacterial infection [1A00-1C4Z] [25]
Cefepime DMHVWIK Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefepime. Bacterial infection [1A00-1C4Z] [15]
Cefpodoxime DMJUNY5 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefpodoxime. Bacterial infection [1A00-1C4Z] [15]
Cefotaxime DMEB837 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefotaxime. Bacterial infection [1A00-1C4Z] [15]
Cefazolin DMPDYFR Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefazolin. Bacterial infection [1A00-1C4Z] [15]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Netilmicin. Bacterial infection [1A00-1C4Z] [15]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Tobramycin. Bacterial infection [1A00-1C4Z] [15]
Cefradine DMUNSWV Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefradine. Bacterial infection [1A00-1C4Z] [15]
Cefixime DMY60I8 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefixime. Bacterial infection [1A00-1C4Z] [15]
Cefoxitin DMY8NC4 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Cefoxitin. Bacterial infection [1A00-1C4Z] [15]
Telithromycin DMZ4P3A Major Decreased metabolism of Nimodipine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [22]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Nimodipine and Cariprazine. Bipolar disorder [6A60] [21]
Erdafitinib DMI782S Moderate Increased metabolism of Nimodipine caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [26]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Nimodipine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Tucatinib DMBESUA Major Decreased metabolism of Nimodipine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
Sotalol DML60TN Moderate Increased risk of cardiac depression by the combination of Nimodipine and Sotalol. Cardiac arrhythmia [BC9Z] [28]
Secobarbital DM14RF5 Moderate Increased metabolism of Nimodipine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [20]
Methohexital DM7YMIT Moderate Increased metabolism of Nimodipine caused by Methohexital mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [20]
Thiopental DMGP8AX Moderate Increased metabolism of Nimodipine caused by Thiopental mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [20]
Mifepristone DMGZQEF Moderate Decreased metabolism of Nimodipine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [15]
Pasireotide DMHM7JS Moderate Increased risk of bradycardia by the combination of Nimodipine and Pasireotide. Cushing syndrome [5A70] [29]
Lumacaftor DMCLWDJ Major Increased metabolism of Nimodipine caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [17]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Nimodipine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [30]
MK-8228 DMOB58Q Moderate Decreased metabolism of Nimodipine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [31]
Aprepitant DM053KT Moderate Decreased metabolism of Nimodipine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [32]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Nimodipine caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [29]
Nefazodone DM4ZS8M Major Decreased metabolism of Nimodipine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [22]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Nimodipine and Selegiline. Depression [6A70-6A7Z] [25]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Nimodipine and Isocarboxazid. Depression [6A70-6A7Z] [25]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Nimodipine and OPC-34712. Depression [6A70-6A7Z] [21]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Nimodipine and Phenelzine. Depression [6A70-6A7Z] [25]
Primidone DM0WX6I Major Increased metabolism of Nimodipine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Nimodipine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [33]
Mephenytoin DM5UGDK Moderate Increased metabolism of Nimodipine caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Cenobamate DM8KLU9 Moderate Increased metabolism of Nimodipine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nimodipine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [36]
Fosphenytoin DMOX3LB Major Increased metabolism of Nimodipine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Ethotoin DMXWOCP Moderate Increased metabolism of Nimodipine caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [34]
Phenobarbital DMXZOCG Major Increased metabolism of Nimodipine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Carbamazepine DMZOLBI Major Increased metabolism of Nimodipine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [17]
Nadolol DMW6GVL Moderate Increased risk of cardiac depression by the combination of Nimodipine and Nadolol. Essential hypertension [BA00] [28]
Tazemetostat DMWP1BH Moderate Increased metabolism of Nimodipine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [37]
Itraconazole DMCR1MV Major Decreased metabolism of Nimodipine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [22]
Miconazole DMPMYE8 Moderate Decreased metabolism of Nimodipine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [38]
Ketoconazole DMPZI3Q Major Decreased metabolism of Nimodipine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [22]
Cimetidine DMH61ZB Moderate Decreased metabolism of Nimodipine caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [39]
Carteolol DMFMDOB Moderate Increased risk of cardiac depression by the combination of Nimodipine and Carteolol. Glaucoma [9C61] [28]
Metipranolol DMJMVKI Moderate Increased risk of cardiac depression by the combination of Nimodipine and Metipranolol. Glaucoma [9C61] [40]
Levobetaxolol DMSREPX Moderate Increased risk of cardiac depression by the combination of Nimodipine and Levobetaxolol. Glaucoma [9C61] [40]
Levobunolol DMTNFCQ Moderate Increased risk of cardiac depression by the combination of Nimodipine and Levobunolol. Glaucoma [9C61] [40]
Carvedilol DMHTEAO Moderate Increased risk of cardiac depression by the combination of Nimodipine and Carvedilol. Heart failure [BD10-BD1Z] [28]
Furosemide DMMQ8ZG Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Furosemide. Heart failure [BD10-BD1Z] [15]
Boceprevir DMBSHMF Major Decreased metabolism of Nimodipine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [22]
Simeprevir DMLUA9D Moderate Decreased metabolism of Nimodipine caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [41]
Telaprevir DMMRV29 Major Decreased metabolism of Nimodipine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [22]
Rifampin DMA8J1G Major Increased metabolism of Nimodipine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [17]
Rifapentine DMCHV4I Major Increased metabolism of Nimodipine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [42]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Nimodipine and Procarbazine. Hodgkin lymphoma [2B30] [25]
Delavirdine DM3NF5G Major Decreased metabolism of Nimodipine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Nimodipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Cobicistat DM6L4H2 Major Decreased metabolism of Nimodipine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Efavirenz DMC0GSJ Moderate Increased metabolism of Nimodipine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [44]
Saquinavir DMG814N Major Decreased metabolism of Nimodipine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Etravirine DMGV8QU Moderate Increased metabolism of Nimodipine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [45]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Nimodipine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Darunavir DMN3GCH Moderate Decreased metabolism of Nimodipine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [46]
Atazanavir DMSYRBX Major Decreased metabolism of Nimodipine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Ritonavir DMU764S Major Decreased metabolism of Nimodipine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [22]
Acebutolol DM0TI4U Moderate Increased risk of cardiac depression by the combination of Nimodipine and Acebutolol. Hypertension [BA00-BA04] [28]
Bisoprolol DM3UZ95 Moderate Increased risk of cardiac depression by the combination of Nimodipine and Bisoprolol. Hypertension [BA00-BA04] [28]
Penbutolol DM4ES8F Moderate Increased risk of cardiac depression by the combination of Nimodipine and Penbutolol. Hypertension [BA00-BA04] [28]
Nebivolol DM7F1PA Moderate Increased risk of cardiac depression by the combination of Nimodipine and Nebivolol. Hypertension [BA00-BA04] [28]
Labetalol DMK8U72 Moderate Increased risk of cardiac depression by the combination of Nimodipine and Labetalol. Hypertension [BA00-BA04] [28]
Conivaptan DM1V329 Major Decreased metabolism of Nimodipine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [22]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [15]
Lesinurad DMUR64T Moderate Increased metabolism of Nimodipine caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [47]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nimodipine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [48]
Amobarbital DM0GQ8N Moderate Increased metabolism of Nimodipine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [20]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Nimodipine and Propiomazine. Insomnia [7A00-7A0Z] [21]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Nimodipine and ITI-007. Insomnia [7A00-7A0Z] [21]
Selpercatinib DMZR15V Moderate Decreased metabolism of Nimodipine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [19]
Idelalisib DM602WT Major Decreased metabolism of Nimodipine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [22]
IPI-145 DMWA24P Moderate Decreased metabolism of Nimodipine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [49]
Propranolol DM79NTF Moderate Increased risk of cardiac depression by the combination of Nimodipine and Propranolol. Migraine [8A80] [28]
Exjade DMHPRWG Moderate Decreased metabolism of Nimodipine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [50]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Nimodipine and Thalidomide. Multiple myeloma [2A83] [15]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Nimodipine and Siponimod. Multiple sclerosis [8A40] [15]
Fingolimod DM5JVAN Moderate Increased risk of bradycardia by the combination of Nimodipine and Fingolimod. Multiple sclerosis [8A40] [51]
Ozanimod DMT6AM2 Moderate Increased risk of bradycardia by the combination of Nimodipine and Ozanimod. Multiple sclerosis [8A40] [52]
Rifabutin DM1YBHK Major Increased metabolism of Nimodipine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [42]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nimodipine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Nilotinib DM7HXWT Moderate Decreased metabolism of Nimodipine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [53]
Imatinib DM7RJXL Moderate Decreased metabolism of Nimodipine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [54]
Dasatinib DMJV2EK Moderate Decreased metabolism of Nimodipine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Modafinil DMYILBE Moderate Increased metabolism of Nimodipine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [15]
Entrectinib DMMPTLH Moderate Decreased metabolism of Nimodipine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [56]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Nimodipine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [57]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Nimodipine and Rasagiline. Parkinsonism [8A00] [25]
Lefamulin DME6G97 Moderate Decreased metabolism of Nimodipine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [58]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Nimodipine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [22]
Enzalutamide DMGL19D Major Increased metabolism of Nimodipine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [17]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Nimodipine due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [19]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Nimodipine and Levomepromazine. Psychotic disorder [6A20-6A25] [21]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Nimodipine and Fluphenazine. Psychotic disorder [6A20-6A25] [21]
Triflupromazine DMKFQJP Moderate Additive hypotensive effects by the combination of Nimodipine and Triflupromazine. Psychotic disorder [6A20-6A25] [21]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Nimodipine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [59]
Tocilizumab DM7J6OR Moderate Altered metabolism of Nimodipine due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [19]
Canakinumab DM8HLO5 Moderate Altered metabolism of Nimodipine due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [19]
Rilonacept DMGLUQS Moderate Altered metabolism of Nimodipine due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [19]
Golimumab DMHZV7X Moderate Altered metabolism of Nimodipine due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [19]
Sarilumab DMOGNXY Moderate Altered metabolism of Nimodipine due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [19]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Nimodipine and Quetiapine. Schizophrenia [6A20] [21]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Nimodipine and Mesoridazine. Schizophrenia [6A20] [21]
Thioridazine DM35M8J Moderate Additive hypotensive effects by the combination of Nimodipine and Thioridazine. Schizophrenia [6A20] [21]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Nimodipine and Aripiprazole. Schizophrenia [6A20] [21]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Nimodipine and Iloperidone. Schizophrenia [6A20] [21]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Nimodipine and Paliperidone. Schizophrenia [6A20] [21]
Loxapine DM8AI9U Moderate Additive hypotensive effects by the combination of Nimodipine and Loxapine. Schizophrenia [6A20] [21]
Haloperidol DM96SE0 Moderate Additive hypotensive effects by the combination of Nimodipine and Haloperidol. Schizophrenia [6A20] [21]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Nimodipine and Perphenazine. Schizophrenia [6A20] [21]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Nimodipine and Molindone. Schizophrenia [6A20] [21]
Chlorpromazine DMBGZI3 Moderate Additive hypotensive effects by the combination of Nimodipine and Chlorpromazine. Schizophrenia [6A20] [21]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Nimodipine and Thiothixene. Schizophrenia [6A20] [21]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Nimodipine and Risperidone. Schizophrenia [6A20] [21]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Nimodipine and Amisulpride. Schizophrenia [6A20] [21]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Nimodipine and Asenapine. Schizophrenia [6A20] [21]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Nimodipine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [60]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Nimodipine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [19]
Larotrectinib DM26CQR Moderate Decreased metabolism of Nimodipine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
Ifosfamide DMCT3I8 Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [15]
Armodafinil DMGB035 Moderate Increased metabolism of Nimodipine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
LEE011 DMMX75K Moderate Decreased metabolism of Nimodipine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [61]
Pitolisant DM8RFNJ Moderate Increased metabolism of Nimodipine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [19]
Fostamatinib DM6AUHV Moderate Decreased clearance of Nimodipine due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [62]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Nimodipine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [59]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Plazomicin. Urinary tract infection [GC08] [15]
Nalidixic acid DMRM0JV Moderate Increased risk of nephrotoxicity by the combination of Nimodipine and Nalidixic acid. Urinary tract infection [GC08] [15]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Nimodipine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [21]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Nimodipine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [63]
⏷ Show the Full List of 162 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Ferrosoferric oxide E00231 14789 Colorant
Glycerin E00026 753 Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Medium-chain triglyceride E00640 Not Available Emollient; Lubricant; Surfactant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nimodipine 30 mg capsule 30 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2523).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
6 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
7 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8 Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):690-4.
9 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
10 Nimodipine inhibits intestinal and aortic smooth muscle contraction by regulating Ca(2+)-activated Cl(-) channels. Toxicol Appl Pharmacol. 2021 Jun 15;421:115543. doi: 10.1016/j.taap.2021.115543. Epub 2021 Apr 16.
11 [Effect of nimodipine on mechanisms of HL-60 cell apoptosis induced by cytarabine]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Feb;15(1):72-5.
12 Palmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease. Toxicol Sci. 2012 Oct;129(2):346-62. doi: 10.1093/toxsci/kfs208. Epub 2012 Jun 14.
13 Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
14 Selection of drugs to test the specificity of the Tg.AC assay by screening for induction of the gadd153 promoter in vitro. Toxicol Sci. 2003 Aug;74(2):260-70. doi: 10.1093/toxsci/kfg113. Epub 2003 May 2.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
17 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
18 Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
21 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
22 Product Information. Nimotop (nimodipine). Bayer, West Haven, CT.
23 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
24 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
25 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
26 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
27 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
28 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
29 Canadian Pharmacists Association.
30 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
31 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
32 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
33 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
34 Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
35 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
36 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
37 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
38 Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
39 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
40 Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
41 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
42 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
43 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
44 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
45 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
46 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
47 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
48 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
49 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
50 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
51 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
53 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
54 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
55 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
56 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
57 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
58 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
59 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
60 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
61 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
62 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
63 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.